Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30057702 | 1.00 | MAPT (0.49) | MAPTNPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL2144418 | 0.86 | KMT2A (0.62) | MAPTNPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL13942781 | 0.86 | ALDH1A1 (0.54) | MAPTNPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL11459379 | 0.86 | CHRNB2 (0.53) | MAPTNPC1RAB9AALDH1A1PKM | |
| SCHEMBL25002111 | 0.86 | MAPK8 (0.49) | MAPTNPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL30168327 | 0.86 | MAPK8 (0.49) | MAPTNPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL7841708 | 0.85 | ALDH1A1 (0.48) | MAPTNPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL2144277 | 0.85 | MAPK8 (0.55) | MAPTNPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL18483932 | 0.84 | CHRNB2 (0.47) | MAPTNPC1RAB9AALDH1A1PKM | |
| SCHEMBL22971083 | 0.82 | GRM5 (0.50) | MAPTNPC1RAB9ANPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558360-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | ALFASIGMA S.P.A. (IT) | 2026-02-24 | — | — | US | disclosed |
| US-20250289816-A1 | SALTS AND PHARMACUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ALFASIGMA S.P.A. (IT) | 2025-09-18 | — | — | US | disclosed |
| US-12234235-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | ALFASIGMA S.P.A. (IT) | 2025-02-25 | — | — | US | disclosed |
| US-20240325405-A1 | COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2024-10-03 | — | — | US | disclosed |
| US-12042498-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | ALFASIGMA S.P.A. (IT) | 2024-07-23 | — | — | US | disclosed |
| US-20230406857-A1 | SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ALFASIGMA S.P.A. (IT) | 2023-12-21 | — | — | US | disclosed |
| EP-3283114-B1 | METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | GALAPAGOS NV (BE) | 2023-09-06 | — | — | EP | disclosed |
| US-11667633-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2023-06-06 | — | — | US | disclosed |
| US-11667633-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2023-06-06 | — | — | US | disclosed |
| US-11667633-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2023-06-06 | — | — | US | disclosed |
| WO-2010010191-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES. | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010191-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES. | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010187-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010187-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009155565-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009068482-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009047514-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047514-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009027283-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO S.A. (CH) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325405-A1 | COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, BMP6, JAK1 | MAPT 4041/4885NPC1 3928/4885RAB9A 2122/4885 |
| US-12558360-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | JAK1, IL6, STAT3 | MAPT 307/4885NPC1 1436/4885RAB9A 3094/4885 |
| US-11667633-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL6, JAK1, COL1A1 | MAPT 4388/4885NPC1 1228/4885RAB9A 1508/4885 |
| US-12234235-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL6, JAK1, COL1A1 | MAPT 4388/4885NPC1 1228/4885RAB9A 1508/4885 |
| US-12042498-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | IL6, JAK1, BMP6 | MAPT 4002/4885NPC1 3627/4885RAB9A 2127/4885 |
| US-20250289816-A1 | SALTS AND PHARMACUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL6, JAK1, BMP6 | MAPT 4367/4885NPC1 1774/4885RAB9A 2136/4885 |
| US-20230406857-A1 | SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL6, JAK1, COL1A1 | MAPT 4388/4885NPC1 1228/4885RAB9A 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.